EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)



Status:Recruiting
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - 85
Updated:4/26/2018
Start Date:March 2, 2017
End Date:March 30, 2020
Contact:Pamela Monds
Email:pamela.monds@duke.edu
Phone:919-668-8695

Use our guide to learn which trials are right for you!

The primary objective of the study is to determine whether, in patients with symptomatic,
advanced heart failure due to left ventricular systolic dysfunction, treatment with LCZ696
for 24 weeks will improve Pro-B-type Natriuretic Peptide (NT-proBNP) levels, which reflect
hemodynamic and clinical status, compared to treatment with valsartan.

Patients with advanced heart failure with reduced ejection fraction (HFrEF) have extremely
high morbidity and mortality with 1 year outcomes of death and hospitalization of
approximately 50%. For the most advanced heart failure patients, the evidence base for
medical treatment is limited with consensus guidelines recommending consideration for either
cardiac transplant or ventricular assist device, or palliative care.

The PARADIGM-HF trial showed that LCZ696, which consists of the neprilysin inhibitor
sacubitril and the ARB valsartan, improved morbidity and mortality in patients with chronic
HFrEF in comparison to enalapril. However, limited experience with advanced heart failure
patients was gained from patients enrolled in the trial. Because the information on the
effects of sacubitril/valsartan in patients with NYHA class IV heart failure is limited, the
updated 2016 ACC/AHA/HFSA guidelines for the treatment of heart failure do not yet endorse
the use of sacubitril/valsartan in patients with NYHA class IV heart failure. Accordingly,
experience is needed on the use of, and outcomes with LCZ696 in patients unable to tolerate
target doses of angiotensin-converting enzyme inhibitor (ACEI)/ angiotensin receptor blocker
(ARB).

This study will be a randomized, double-blinded trial of advanced heart failure subjects with
1:1 randomization to either LCZ696 (sacubitril and valsartan) or valsartan. Study drug will
be administered in a double-dummy fashion, in which subjects take active (LCZ696 or
valsartan) and placebo. Approximately 400 subjects will be randomized into the study.

Subjects will have an initial screening evaluation, including baseline laboratory tests as
well as an assessment of left ventricular (LV) ejection fraction, at which time preliminary
subject eligibility will be determined. The LV ejection fraction may have been obtained
within the prior 3 months by 2-D echocardiogram, LV angiogram or radionuclide scintigraphy.
Willing subjects meeting entry criteria will be consented. Those who meet all entry criteria
and are interested in study participation will be enrolled.

Enrolled subjects will complete baseline assessments and undergo a run-in period of 3-7 days
with LCZ696 50 mg (equivalent to Entresto™ 24/26 mg) po BID prior to randomization. For
subjects taking an ACEI, the ACEI will be withheld for ≥ 36 hours prior to first dose of
LCZ696.

Subjects who tolerate the run-in period with LCZ696 will be randomized 1:1 to LCZ696 or
valsartan.

Study treatment will be titrated to the target dose of 200 mg LCZ696 (equivalent to Entresto™
97/103 mg) as two 100 mg LCZ696 and 2 placebo tablets po BID or valsartan 160 mg (two 80 mg
valsartan and 2 placebo tablets) po BID.*

Randomized subjects will receive the first dose of study drug as follows:

- For subjects not previously taking ACEI or ARB, previously taking ACEI or ARB at a low
dose*, or subjects who have an eGFR < 30 mL/min/1.73m², the starting dose of valsartan
will be 40 mg po BID and the starting dose of LCZ696 will be 50 mg po BID.

- For subjects taking an ARB at greater than low dose†, the starting dose of valsartan
will be 80 mg po BID and the starting dose of LCZ696 will be 100 mg po BID.*

- For subjects taking an ACEI at greater than low dose†, the ACEI will be withheld for ≥
36 hours prior to randomization. The starting dose of valsartan will be 80 mg po BID and
the starting dose of LCZ696 will be 100 mg po BID.*

- At Investigator discretion, study drug may be started at the low dose
(LCZ696/placebo 50 mg po BID or valsartan/placebo 40 mg po BID) if there are any
concerns regarding tolerability at the 100 mg / 80 mg dose.)

Per package insert, the valsartan compounded in Entresto™ is more bioavailable than the
valsartan in other marketed formulations. The dose equivalence for valsartan compounded in
Entresto™ compared to valsartan prepared alone (Entresto™ dose = marketed valsartan dose) is
as follows: 26 mg=40 mg, 51 mg=80 mg, 103 mg=160 mg.

† Low dose is defined as 24 hour dose of ≤ 10 mg lisinopril, ≤ 5 mg ramipril, ≤ 50 mg
losartan, ≤ 10 mg olmesartan, or other dose equivalent.

Dose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 or valsartan
up to the target maximum dose. The doses of LCZ696 are 50 mg (one 50 mg active and 1 placebo
tablet), 100 mg (one 100 mg active and 1 placebo tablet) and 200 mg (two 100 mg active and 2
placebo tablets). These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial
Entresto™, respectively. The doses of valsartan are 40mg (one 40 mg active and 1 placebo
tablet), 80 mg (one 80 mg active and 1 placebo tablet), and 160 mg (two 80 mg active and 2
placebo tablets). The criteria for doubling the dose will be based on systolic blood pressure
(a SBP > 90 mmHg is required for up titration), changes in renal function (maximum serum
creatinine of 2.0 mg/dL), and the absence of symptoms of hypotension. For those not
tolerating the current dose of study drug, the dose will be down-titrated to the previous
tolerated dose. Subjects will return to clinic for follow-up visits at 2, 4, 8, 12, and 24
weeks after randomization.

Assessments at the follow-up visits include some or all of the following: medical history,
review of medications, physical examination with the New York Heart Association (NYHA) class
assessment, Kansas City Cardiomyopathy Questionnaire (KCCQ) quality of life questionnaire,
local laboratory testing (creatinine, Blood Urea Nitrogen (BUN), electrolytes), Core
laboratory testing (Cystatin C, NT-proBNP), adherence and tolerance assessment, and adverse
event monitoring.

Follow-up phone calls will be made at 10, 16, and 20, weeks after randomization to assess
dosing compliance, record the occurrence of applicable adverse events and events of interest,
and remind the subject of the date and time of their next in-person visit.

A final phone visit is conducted 2 weeks after the last dose of study drug (26 weeks after
randomization) to assess clinical stability and any applicable adverse events.

During the consent process, subjects will be asked if interested in donating samples and data
for research purposes via a biorepository and/or genetic study. Based on site and IRB
preference, this optional part of the study may be incorporated into the main consent or may
be a separate consent and Institutional Review Board (IRB) application.

Inclusion Criteria:

1. Advanced HFrEF defined as including ALL

1. LVEF≤ 35% documented during the preceding 12 months

2. NYHA class IV symptomatology, defined as chronic dyspnea or fatigue at rest or on
minimal exertion in the previous 3 months, or patients who require chronic
inotropic therapy

3. Minimum of 3 months GDMT for HF and/or intolerant to therapy

2. Systolic blood pressure ≥ 90 mmHg

3. Serum NT-proBNP ≥ 800 pg/mL OR BNP ≥ 250 pg/mL (most recent - less than 3 months old)

4. Any one or more of the following objective findings of advanced HF including:

1. Current inotropic therapy or use of inotropes in the past 6 months

2. ≥ 1 hospitalization for heart failure in the past 6 months (not including the
index hospitalization for inpatient participants)

3. LVEF ≤ 25% (within the past 12 months)

4. Peak VO2 < 55% predicted or peak VO2 ≤ 16 for men or ≤ 14 for women (Respiratory
Exchange Ratio (RER) ≥ 1.05) (within the past 12 months)

5. 6 min walk test distance < 300 m (within the past 3 months)

5. Age ≥18 years and ≤ 85 years

6. Signed Informed Consent form

Exclusion Criteria:

1. Currently taking Entresto™

2. History of hypersensitivity or intolerance to Entresto™, an ACEI or ARB as well as
known or suspected contraindications to the study drugs.

3. Estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73 m2 at baseline

4. Co-morbid conditions that may interfere with completing the study protocol (e.g.
recent history of drug or alcohol abuse) or cause death within 1 year

5. Symptomatic hypotension at randomization or systolic blood pressure < 90 mmHg

6. Serum potassium > 5.5 mmol/L

7. Severe liver dysfunction (Childs-Pugh Class C)

8. Acute coronary syndrome within 4 weeks as defined by electrocardiographic (ECG)
changes and biomarkers of myocardial necrosis (e.g. troponin) in an appropriate
clinical setting (chest discomfort or anginal equivalent)

9. Planned or recent (≤ 4 weeks) PCI, coronary artery bypass grafting, or biventricular
pacing

10. Currently hospitalized and listed 1A or 1B for transplant

11. Current or scheduled for LVAD implantation within 30 days of study enrollment

12. Active infection (current use of oral or IV antimicrobial agents)

13. Primary hypertrophic or infiltrative cardiomyopathy, acute myocarditis, constrictive
pericarditis or tamponade

14. Complex congenital heart disease

15. Concomitant use of aliskiren in patients with diabetes or renal impairment (eGFR <60
mL/min/1.73 m²)

16. Known pregnancy or anticipated pregnancy within the next 6 months or breastfeeding
mothers

17. Enrollment in any other investigational clinical trial within 30 days prior to
screening

18. Inability to comply with study procedures
We found this trial at
39
sites
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Kenneth Margulies, MD
Phone: 215-662-4214
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
1648 Pierce Dr NE
Atlanta, Georgia 30322
(404) 727-5640
Principal Investigator: Gupta Divya, MD
Phone: 404-712-0531
Emory University School of Medicine Emory University School of Medicine has 2,359 full- and part-time...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Gregory Lewis, MD
Phone: 617-726-8228
?
mi
from
Boston, MA
Click here to add this to my saved trials
800 Washington St
Boston, Massachusetts 02111
(617) 636-5000
Principal Investigator: Michael Kiernan, MD
Phone: 617-636-4990
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
?
mi
from
Boston, MA
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Michael Givertz, MD
Phone: 617-732-7174
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
1000 Blythe Blvd
Charlotte, North Carolina 28203
(704) 355-2000
Principal Investigator: Sanjeev Gulati, MD
Phone: 704-355-4795
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Randall Starling, MD
Phone: 216-445-1766
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Principal Investigator: Mary Keebler, MD
Phone: 615-322-2318
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: James Mudd, MD
Phone: 503-494-7400
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Donald Haas, MD
Phone: 215-481-4661
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
1500 E Medical Center Dr
Ann Arbor, Michigan 48109
(734) 936-4000
Principal Investigator: Maryse Palardy, MD
Phone: 734-232-4606
University of Michigan Health System The University of Michigan is home to one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Atlanta, Georgia 30309
Principal Investigator: Arun Krishnamoorthy, MD
Phone: 404-605-2409
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1800 Orleans St.
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Nisha Gilotra, MD
Phone: 410-502-3173
Johns Hopkins Hospital Patients are the focus of everything we do at The Johns Hopkins...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Beverly Hills, California 90211
Principal Investigator: Evan Kransdorf, MD
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
2139 Auburn Ave
Cincinnati, Ohio 45219
(513) 585-2000
Principal Investigator: Gregory Egnaczyk, MD
Phone: 513-585-1478
The Christ Hospital For more than 120 years, The Christ Hospital has been a leader...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cleveland, Ohio 44194
Principal Investigator: Guilherme Oliveria, MD
Phone: 216-983-4724
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Cleveland, Ohio 44109
Principal Investigator: Mark Dunlap, MD
Phone: 216-778-2223
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Brent Lampert, MD
Phone: 614-247-7133
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Durham, North Carolina 27710
Principal Investigator: Adam DeVore, MD
Phone: 919-668-8222
?
mi
from
Durham, NC
Click here to add this to my saved trials
Falls Church, Virginia 22042
Principal Investigator: Palak Shah, MD
Phone: 703-776-3697
?
mi
from
Falls Church, VA
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Arvind Bhimaraj, MD
Phone: 713-441-3963
?
mi
from
Houston, TX
Click here to add this to my saved trials
Indianapolis, Indiana 46290
Principal Investigator: Ashwin Ravichandran, MD
Phone: 317-338-6151
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
New Orleans, Louisiana 70121
Principal Investigator: Clement Eisworth Jr, MD
Phone: 504-842-8702
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
New York, New York 10029
Principal Investigator: Anu Lala-Trindade, MD
Phone: 212-241-7300
?
mi
from
New York, NY
Click here to add this to my saved trials
600 Gresham Dr
Norfolk, Virginia 23507
(757) 388-3000
Principal Investigator: John Herre, MD
Phone: 757-388-3529
Sentara Norfolk General Hospital Sentara Norfolk General Hospital is recognized as the number one ranked...
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
4440 West 95th Street
Oak Lawn, Illinois 60453
708.684.8000
Principal Investigator: Geetha Bhat, MD
Phone: 708-684-4690
Advocate Christ Medical Center Advocate Health Care, named among the nation
?
mi
from
Oak Lawn, IL
Click here to add this to my saved trials
Oklahoma City, Oklahoma
Principal Investigator: Douglas Hostmanshof, MD
Phone: 405-713-9900
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
111 S 11th St
Philadelphia, Pennsylvania 19107
(215) 955-6000
Principal Investigator: David Whellan, MD
Phone: 215-955-8848
Thomas Jefferson University Hospital Our hospitals in Center City Philadelphia share a 13-acre campus with...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
320 E North Ave
Pittsburgh, Pennsylvania 15212
(412) 359-3131
Principal Investigator: Manreet Kumar, MD
Phone: 412-359-6908
Allegheny General Hospital At Allegheny General Hospital, our physicians and healthcare staff have earned an...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Margaret Redfield, MD
Phone: 507-538-7177
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Sacramento, California 95816
Principal Investigator: Zijian Xu, MD
Phone: 916-833-8576
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Justin Vader, MD
Phone: 314-286-1767
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
3635 Vista at Grand Ave.
Saint Louis, Missouri 63110
Principal Investigator: Paul Hauptman, MD
Phone: 314-577-8876
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Salt Lake City, Utah 84132
Principal Investigator: Omar Wever-Pinzon, MD
Phone: 801-213-3417
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Diego, California 92123
Principal Investigator: Hirsh Mehta, MD
Phone: 858-244-6886
?
mi
from
San Diego, CA
Click here to add this to my saved trials
1959 NE Pacific St
Seattle, Washington 98195
(206) 598-3300
Principal Investigator: Claudius Mahr, MD
Phone: 206-685-4346
University of Washington Medical Center University of Washington Medical Center is one of the nation's...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
101 Nicolls Rd
Stony Brook, New York 11794
(631) 444-4000
Principal Investigator: Hal Skopicki, MD
Phone: 631-444-2031
Stony Brook University Medical Center Stony Brook Medicine expresses our shared mission of research, clinical...
?
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Washington, District of Columbia
Principal Investigator: Selma Mohammed, MD
Phone: 202-877-0572
?
mi
from
Washington,
Click here to add this to my saved trials
1000 East Mountain Boulevard
Wilkes-Barre, Pennsylvania 18711
Principal Investigator: Sanjay Doddamani, MD
Phone: 570-808-3461
?
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials